AI could revolutionize liver cancer treatment: study aims to predict who benefits from combination therapy
NCT ID NCT07584317
First seen May 15, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study will test whether an artificial intelligence (AI) model can accurately predict how well liver cancer patients respond to a combination of treatments: TACE (a procedure that blocks blood flow to the tumor), immunotherapy, and targeted therapy. Researchers will collect data from 1,170 participants to train and validate the AI model. The goal is to personalize treatment decisions and improve outcomes for people with hepatocellular carcinoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.